Halozyme Therapeutics Inc (HALO)

[friendofthedevil]

I guess so. Remember that HR = 1.0 means the two groups have no difference. The lower the HR, the more separation there is between groups.

Regardless of the HR, I would be cautious in making too much from the stage 1 Ph2 efficacy data. The best thing we know from the 202 trial so far is that LMWH makes it safe to run the 301 trial.

I have been critical in the past of the strength of the stage 1 efficacy data. The large number of subjects with HA status that is undetermined, the 'meh' OS data, as well as the increase in the HR when a hand picked sub group was tested with the new HA method all undermines my faith in the trial data (so far). I am eagerly awaiting 202 data in the fall. At least the PFS should be available and I will look it over closely.

The overall biotech market has been brutal this year and I'm not sure biotech will get out of this funk in 2016. I hope I'm wrong. But any company that might have to raise in the near term could have issues with dilution. The $150 million raise HALO did was brilliant but the rate at which they are spending it was disappointing. Because of this, I have since cut back on my overweight investment here to represent a more average share of my portfolio. I will be watching the balance sheet as well as the PEG results to see if or when I will increase exposure.